RE:Bloomberg PR on pancreatic cancer players"Several biotech developers have been making strides
against the deadly disease, including a new mRNA vaccine in the works from
BioNTech SE (NASDAQ:BNTX), as well as promising drug-combo therapies from O
ncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Seagen Inc. (NASDAQ:SGEN),
and better diagnostics from Myriad Genetics, Inc. (NASDAQ:MYGN) and
Illumina, Inc. (NASDAQ:ILMN)."
ONCY is now being included in the list of top-tier Big Pharma companies that are working to find a treatment for pancreatic cancer.
ONCY is the only company that is targeting advanced or metastatic pancreatic cancer,
in which the 1 year survival rate is only 10%.
The others have targeted the earlier and less aggressive stages of pancreatic cancer, where the 5 year survival rate is now around 12 %.